Can Upadacitinib (Rinvoq) Be Safely Co-Administered with Rosuvastatin?
Yes, upadacitinib and rosuvastatin can be safely co-administered without dose adjustments or special monitoring beyond standard clinical practice. There are no clinically significant drug-drug interactions between these medications.
Rationale Based on Pharmacology
Upadacitinib is primarily metabolized through hepatic oxidation with minimal CYP450 involvement 1. The FDA label specifically identifies only two clinically relevant drug interactions for upadacitinib:
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit) - which may require dose adjustments depending on the indication 1
- Strong CYP3A4 inducers (rifampin) - which are not recommended for co-administration 1
Rosuvastatin is not metabolized by CYP3A4. Instead, it undergoes minimal metabolism via CYP2C9 and is primarily eliminated unchanged 2. This fundamental difference in metabolic pathways means there is no mechanistic basis for a pharmacokinetic interaction between these two drugs.
Supporting Evidence from Guidelines
The American Heart Association's 2016 scientific statement on statin drug interactions explicitly addresses rosuvastatin's favorable interaction profile. Rosuvastatin is recommended as a preferred non-CYP3A4-metabolized statin specifically because it avoids interactions with drugs that affect the CYP3A4 pathway 2. The guideline states that rosuvastatin can be safely combined with various cardiovascular agents, including amiodarone, warfarin, and calcium channel blockers, without significant interactions 2.
Clinical Evidence from JAK Inhibitor Studies
Research on peficitinib (another JAK inhibitor) demonstrated that co-administration with rosuvastatin resulted in only an 18% increase in rosuvastatin AUC and 15% increase in Cmax - changes deemed not clinically significant 3. This study specifically evaluated the OATP1B1 transporter interaction and concluded no dose adjustments were necessary.
While this study evaluated peficitinib rather than upadacitinib, it provides reassuring evidence that JAK inhibitors as a class do not produce clinically meaningful interactions with rosuvastatin.
Practical Clinical Approach
No dose adjustments are needed for either medication when co-administered 1. Standard monitoring for both drugs should continue:
- For rosuvastatin: Monitor lipid panels per standard guidelines and assess for muscle symptoms (myalgia, weakness) as with any statin therapy
- For upadacitinib: Follow indication-specific monitoring per FDA label, including periodic assessment of lipid profiles, liver enzymes, and complete blood counts 1
Important Caveats
The lipid monitoring recommended for upadacitinib is not due to a drug interaction with rosuvastatin, but rather because JAK inhibitors can independently affect lipid metabolism 4. Some patients on upadacitinib may experience increases in LDL and total cholesterol, which may necessitate statin dose optimization based on lipid targets - but this is a disease/drug effect, not an interaction.
Avoid confusing this scenario with simvastatin or lovastatin, which ARE metabolized by CYP3A4 and would theoretically have different considerations if strong CYP3A4 inhibitors were added to the regimen. Rosuvastatin's non-CYP3A4 metabolism makes it an ideal choice when drug interaction concerns exist 2.